EUVIMEDEUVIMED entdecken
Crossref

Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S

Abdullah Khalid, Zohaa Faiz, Manav Shah, Elliot Newman, Daniel A King, Danielle DePeralta, Sepideh Gholami, Matthew J Weiss, Marcovalerio Melis

Journal of Gastrointestinal Cancer · 2025

DOI: 10.1007/s12029-024-01119-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, 2025. Verfasst von Abdullah Khalid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Northwell Health, North Shore/Long Island Jewish General Surgery, 300 Community Dr., Manhasset, NY, USA. akhalid7@northwell.edu. Hauptthemen laut MEDLINE: Immunotherapy, Pancreatic Neoplasms, Socioeconomic Factors, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer with a poor prognosis, is expected to become the second deadliest cancer in the United States by 2030. Despite advancements in treatment modalities, the survival rates of patients with PDAC have remained low. Immunotherapy has emerged as a promising treatment for various cancers; however, its utilization in PDAC has been limited due to various challenges, including resistance mechanisms and the advanced stage at which most patients are diagnosed. METHODS: We analyzed data from the National Cancer Database (NCDB) from 2010 to 2017, focusing on the impact of race, insurance status, and socioeconomic factors among patients with stage IV PDAC using logistic regression analyses. RESULTS: Among 109,663 patients with stage IV PDAC, 421 (0.38%) received immunotherapy. The recipients were younger (median age 63 vs. 68 years, p < 0.001) and more likely to be white (87.4% vs. 82.1%). Patients with private insurance or Medicare (p < 0.001), and those earning more than $60 k annually (51.0% vs. 36.4%, p < 0.001) were more likely to receive immunotherapy. Treatment was more likely in academic/research programs than in community cancer programs (53.0% vs. 33.4%, p < 0.001). On multivariate analysis, Black patients had lower odds of receiving immunotherapy than Caucasian patients (OR: 0.74 [95% CI: 0.601-0.882], p = 0.019). Higher income was also a significant predictor of immunotherapy utilization (highest vs. lowest income quartile: OR, 2.228 [95% CI: 1.422-3.491], p < 0.001). CONCLUSIONS: This study revealed significant disparities in immunotherapy access for stage IV PDAC based on race, socioeconomic status, and geographic location in the United States, highlighting the need for intervention to promote equitable access to this promising treatment modality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyPancreatic NeoplasmsSocioeconomic FactorsCarcinoma, Pancreatic DuctalNeoplasm StagingHumansFemaleMaleUnited StatesMiddle AgedAgedHealthcare Disparities

Stichwörter der Autor:innen

Access to careHealth disparitiesImmunotherapyPancreatic cancerSocioeconomic factors

Autor:innen und Institutionen

  • Northwell Health, North Shore/Long Island Jewish General Surgery, 300 Community Dr., Manhasset, NY, USA. akhalid7@northwell.edu.
  • Department of Medicine, Aga Khan University, Karachi, Pakistan.
  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
  • Northwell Health Lenox Hill Hospital, 100 E 77Th St, New York, NY, USA.
  • Northwell Health Cancer Institute, 1111 Marcus Ave, New Hyde Park, NY, USA.

Zitieren

APA

Khalid, A., Faiz, Z., Shah, M., Newman, E., King, D. A., DePeralta, D., Gholami, S., Weiss, M. J., & Melis, M. (2025). Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01119-2

Vancouver

Khalid A, Faiz Z, Shah M, Newman E, King DA, DePeralta D, et al. Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. Journal of Gastrointestinal Cancer. 2025. doi:10.1007/s12029-024-01119-2

BibTeX
@article{Khalid2025,
  author = {Khalid, Abdullah and Faiz, Zohaa and Shah, Manav and Newman, Elliot and King, Daniel A and DePeralta, Danielle and Gholami, Sepideh and Weiss, Matthew J and Melis, Marcovalerio},
  title = {Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2025},
  doi = {10.1007/s12029-024-01119-2}
}
Kostenlos starten →